CAR-T（CAR-T）细胞疗法在非肿瘤性疾病中的应用
Chimeric antigen receptor T (CAR-T) cell therapy in non-oncological diseases.
CAR-T（CAR-T）细胞在血液系统恶性肿瘤中的应用推动了这种免疫治疗形式的显著进展。
CELL INTELLIGENCE · 肿瘤细胞治疗研究
肿瘤细胞治疗研究
CAR-T 细胞治疗中桥接治疗的作用
英文原题：Role of bridging therapy during chimeric antigen receptor T cell therapy.
查看英文原题
Role of bridging therapy during chimeric antigen receptor T cell therapy.
分数与星级只用于站内排序 —— 不代表疗效、安全性或个人适用性。
中文摘要
嵌合抗原受体（CAR）T细胞疗法已获批用于多种复发/难治性血液系统恶性肿瘤，并显著改善了这些疾病的结局。多种CAR-T 产品已用于临床实践，且真实世界结局与临床试验结果同样优异。然而，CAR-T 应用增加也暴露出导致治疗显著延迟的障碍。因此，桥接治疗已广泛用于白细胞单采和CAR-T 输注之间，以稳定或降低疾病负荷。本文综述桥接治疗的现有数据，重点讨论患者选择、治疗方式选择、治疗时机及潜在陷阱。
展开英文摘要原文
Chimeric antigen receptor (CAR) T-cell therapy has been approved for use in several relapsed/refractory hematologic malignancies and has significantly improved outcomes for these diseases. A number of different CAR T products are now being used in clinical practice and have demonstrated excellent outcomes to those in clinical trials.
However, increased real-world use of CAR T therapy has uncovered a number of barriers that can lead to significant delays in treatment. As a result, bridging therapy has become a widely used tool to stabilize or debulk disease between leukapheresis and CAR T cell administration.
Here we review the available data regarding bridging therapy, with a focus on patient selection, choice of therapy, timing of therapy, and potential pitfalls.
论文信息
- 作者
- Bhaskar ST、Dholaria BR、Sengsayadeth SM、Savani BN、Oluwole OO
- 单位
- Division of Hematology/Oncology Department of Medicine Vanderbilt University Medical Center Nashville Tennessee USA.United States
- 文献类型
- 综述
- 期刊
- EJHaem2022 Jan
- 原文标识
- PubMed 35844303 · DOI 10.1002/jha2.335
在 PubMed 查看 → 出版商原文（DOI） 全文 PDF（PMC）· 可下载 治疗专题与资料阅读指南 资料来源与翻译说明 报告译文或资料问题 →